1. Home
  2. ABEO vs FACT Comparison

ABEO vs FACT Comparison

Compare ABEO & FACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABEO
  • FACT
  • Stock Information
  • Founded
  • ABEO 1974
  • FACT 2024
  • Country
  • ABEO United States
  • FACT United States
  • Employees
  • ABEO N/A
  • FACT N/A
  • Industry
  • ABEO Biotechnology: Pharmaceutical Preparations
  • FACT
  • Sector
  • ABEO Health Care
  • FACT
  • Exchange
  • ABEO Nasdaq
  • FACT NYSE
  • Market Cap
  • ABEO 256.9M
  • FACT 245.6M
  • IPO Year
  • ABEO 1980
  • FACT 2024
  • Fundamental
  • Price
  • ABEO $5.93
  • FACT $10.25
  • Analyst Decision
  • ABEO Strong Buy
  • FACT
  • Analyst Count
  • ABEO 6
  • FACT 0
  • Target Price
  • ABEO $18.00
  • FACT N/A
  • AVG Volume (30 Days)
  • ABEO 870.0K
  • FACT 96.9K
  • Earning Date
  • ABEO 08-11-2025
  • FACT 01-01-0001
  • Dividend Yield
  • ABEO N/A
  • FACT N/A
  • EPS Growth
  • ABEO N/A
  • FACT N/A
  • EPS
  • ABEO N/A
  • FACT N/A
  • Revenue
  • ABEO N/A
  • FACT N/A
  • Revenue This Year
  • ABEO N/A
  • FACT N/A
  • Revenue Next Year
  • ABEO $323.51
  • FACT N/A
  • P/E Ratio
  • ABEO N/A
  • FACT N/A
  • Revenue Growth
  • ABEO N/A
  • FACT N/A
  • 52 Week Low
  • ABEO $3.93
  • FACT $9.85
  • 52 Week High
  • ABEO $7.32
  • FACT $10.32
  • Technical
  • Relative Strength Index (RSI)
  • ABEO 45.53
  • FACT N/A
  • Support Level
  • ABEO $6.10
  • FACT N/A
  • Resistance Level
  • ABEO $6.24
  • FACT N/A
  • Average True Range (ATR)
  • ABEO 0.29
  • FACT 0.00
  • MACD
  • ABEO -0.09
  • FACT 0.00
  • Stochastic Oscillator
  • ABEO 4.26
  • FACT 0.00

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

About FACT FACT II ACQUISITION CORP

FACT II Acquisition Corp is a blank check company.

Share on Social Networks: